Chronic kidney disease (CKD) and chronic kidney insufficiency (CKI) diagnosing equation in cirrhotic patients.


Journal

Nephrology (Carlton, Vic.)
ISSN: 1440-1797
Titre abrégé: Nephrology (Carlton)
Pays: Australia
ID NLM: 9615568

Informations de publication

Date de publication:
Aug 2022
Historique:
revised: 08 05 2022
received: 07 11 2021
accepted: 21 05 2022
pubmed: 10 6 2022
medline: 15 7 2022
entrez: 9 6 2022
Statut: ppublish

Résumé

Cirrhotic patients can develop acute kidney injury (AKI), and chronic kidney disease (CKD). Therefore, renal functional evaluation is crucial in cirrhotic patients. However, serum creatinine and urea levels, as well as measured or estimated glomerular filtration rate is not reliable renal functional markers in these patients compared to other patient groups. In the present study, four original equations are designed and tested for screening chronic kidney disease (CKD) and chronic kidney insufficiency (CKI) in stable cirrhotic patients. estimated GFR (CKD-EPI creatinine and cystatin equations) were recorded in 175 adult stable patients suffering from cirrhosis, and these patients were classified as presenting or not CKD and CKI after evaluation by two independent nephrologists. Based on these data, the variables with the significant discriminating capability to identify CKD and CKI (based on creatinine and cystatin) were detected by applying the Student's t-test for two independent groups, later confirmed by the lambda test of Wilks, in order to obtain the renal function equations. CKD equation (creatinine) = 7.094238-0.043104 × CKD-EPI creatinine - 0.057537 × haematocrit. CKD equation (cystatin) = 8.375074-0.117218 × CKD-EPI cystatin. CKI equation (creatinine) = 0.428389-0.043214 × CKD-EPI creatinine +0.183051 × Child-Pugh score + 0.050162 × age (in years). CKI equation (cystatin) = 9.169579-0.139319 × CKD-EPI cystatin. Simple and reliable equations have been obtained for screening chronic kidney disease and chronic kidney insufficiency in cirrhotic patients.

Identifiants

pubmed: 35678550
doi: 10.1111/nep.14075
doi:

Substances chimiques

Cystatin C 0
Creatinine AYI8EX34EU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

658-662

Informations de copyright

© 2022 Asian Pacific Society of Nephrology.

Références

Gines P, Arroyo V, Rodés J, Schrier R. Ascitis and renal dysfunction in liver disease. Pathogenesis, Diagnosis and Treatment. Oxford. Blackwell Publishing; 2005.
Piano S, Brocca A, Angeli P. Renal function in cirrhosis: a critical review of available tools. Semin Liver Dis. 2018;38(3):230-241. doi:10.1055/s-0038-1661372
Francoz C, Glotz D, Moreau R, Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol. 2010;52(4):605-613. doi:10.1016/j.jhep.2009.11.025
Capalbo O, Giuliani S, Ferrero-Fernández A, Casciato P, Musso CG. Kidney-liver pathophysiological crosstalk: its characteristics and importance. Int Urol Nephrol. 2019;51(12):2203-2207.
Teneva BH. Pathogenesis and assessment of renal function in patients with liver cirrhosis. Folia Med (Plovdiv). 2012;54(4):5-13.
Chen YW, Wu CJ, Chang CW, Lee SY, Sun FJ, Chen HH. Renal function in patients with liver cirrhosis. Nephron Clin Pract. 2011;118(2):c195-c203. doi:10.1159/000321384
Stevens PE. Evaluation and Management of Chronic Kidney Disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med [Internet]. 2013;158(11):825-830.
Musso CG, Álvarez-Gregori J, Jauregui J, Macías-Núñez JF. Glomerular filtration rate equations: a comprehensive review. Int Urol Nephrol. 2016 Jul;48(7):1105-1110.
Rognant N, Lemoine S. Evaluation of renal function in patients with cirrhosis: where are we now? World J Gastroenterol. 2014;20(10):2533-2541.
Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, I Feldman HI, Kusek JW, Eggers P, Van Lente F, T, Coresh J, For the chronic kidney disease epidemiology collaboration (CKD-EPI). A new equation to estimate glomerular filtration rate”. Ann Intern Med 2009;150(9):604-612.
Fede G, D'Amico G, Arvaniti V, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol. 2012;56:810-818.
Charlton MR, Wall WJ, Ojo AO, et al. Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl. 2009;15:S1-S34.
Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931-940.
Aiello F, Bajo M, Marti F, Musso CG. How to evaluate renal function in stable cirrhotic patients. Postgrad Med. 2017;29(8):866-871.
Musso CG, Michelangelo H, Vilas M, et al. Creatinine reabsorption by the aged kidney. Int Urol Nephrol. 2009;41:727-731.
Aiello FI, Bajo M, Mrti F, Gadano A, Musso CG. Model for end-stage liver disease (MELD) score and liver transplant: benefits and concerns. AME Med J. 2017;2:168.
Đorđe Ćulafić D, Štulić M, Obrenović R, et al. Role of cystatin C and renal resistive index in assessment of renal function in patients with liver cirrhosis. World J Gastroenterol. 2014;20(21):6573-6579.

Auteurs

Carlos G Musso (CG)

Research Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Facultad de Ciencias de la Salud, Universidad Simón Bolívar, Barranquilla, Colombia.

Paola Casciato (P)

Hepatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Juan Macías-Nuñez (J)

Cátedra Extraordinaria Fiiperva de Hipertensión, Riesgo Cardiovascular y Geriatría, University of Salamanca, Salamanca, Spain.

Ramón Ardanuy (R)

Cátedra Extraordinaria Fiiperva de Hipertensión, Riesgo Cardiovascular y Geriatría, University of Salamanca, Salamanca, Spain.

Henry Gonzalez-Torres (H)

Facultad de Ciencias de la Salud, Universidad Simón Bolívar, Barranquilla, Colombia.

Gustavo Aroca-Martinez (G)

Facultad de Ciencias de la Salud, Universidad Simón Bolívar, Barranquilla, Colombia.
Universidad del Norte, Barranquilla, Colombia.

Cristina Torres-Caro (C)

Hepatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Adrian Narvaez (A)

Hepatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Mariano Bonifacio (M)

Hepatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Marlene Padilla (M)

Hepatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Adrian Gadano (A)

Research Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Hepatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH